RTP Mobile Logo
An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Lymphoma and Multiple Myeloma
Released August 2017

Proceedings from a CME symposium held at the 2017 ASCO Annual Meeting. Featuring perspectives from Drs Stephen M Ansell, Michelle A Fanale, Christopher Flowers, Jonathan W Friedberg, Noopur Raje and S Vincent Rajkumar. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma (MM) and other related disorders (eg, myelodysplastic syndrome, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that 172,910 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2017 and 58,300 individuals will die from these diseases. Importantly, nearly 70 drug products with more than 120 distinct FDA-approved indications are currently labeled for use in the management of hematologic cancers. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true, however, within the realm of Hodgkin and non-Hodgkin lymphoma (including chronic lymphocytic leukemia [CLL]) and MM, where the past several years have seen a staggering number of important clinical and research advances.

    These video proceedings from a CME symposium held during the 2017 ASCO Annual Meeting feature discussions with leading researchers with expertise in hematologic cancers regarding the latest clinical research findings and actual patient cases from their practices for whom these data sets had the potential to have an impact on care. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge of recent data related to the rapidly evolving hematologic oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.


    • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory MM.
    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory CLL, considering clinical presentation, biomarker profile and psychosocial status.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
    • Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
    • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with Hodgkin lymphoma (HL) and other CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
    • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and/or potential utility of each in clinical practice.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Stephen M Ansell, MD, PhD
    Professor of Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research: Affimed, Bristol-Myers Squibb Company, Celldex Therapeutics, Merck, Pfizer Inc, Seattle Genetics.

    Michelle A Fanale, MD
    Associate Professor 
    Department of Lymphoma and Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Merck, Spectrum Pharmaceuticals Inc; Honoraria: Plexus, Seattle Genetics, Takeda Oncology; Travel: Bristol-Myers Squibb Company, Merck, Plexus, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology and Medical Oncology 
    Emory School of Medicine Winship Cancer Institute 
    Atlanta, Georgia

    Consulting Agreements: AbbVie Inc, Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc; Contracted Research: AbbVie Inc, Acerta Pharma, Eastern Cooperative Oncology Group, Genentech BioOncology, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc.

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center 
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Celgene Corporation, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly.

    S Vincent Rajkumar, MD
    Edward W and Betty Knight Scripps Professor of Medicine
    Division of Hematology
    Chair, Myeloma Amyloidosis Dysproteinemia Group 
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Kite Pharma Inc and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2017
    Expiration date: August 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):